retatrutide diabetes – The New Weight Loss Helper Retatrutide is a new medication being developed by Eli Lilly to help people lose weight. It's like a super version of drugs such as Ozempic Lilly Prepares for Retatrutide FDA

it has multiple programs in the early stages of development to bring next-generation weight-loss pills to market

Medical Eligibility Criteria BMI Requirements (Same as In-Person): You qualify if: BMI 30 (obesity category), OR BMI 27 (overweight category) with at least one weight-related health condition Weight-Related Conditions: Type 2 diabetes or prediabetes Hypertension (high blood pressure) High cholesterol or dyslipidemia Obstructive sleep apnea Cardiovascular disease Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease Osteoarthritis worsened by weight Calculate Your BMI: BMI = (Weight in pounds / Height in inches) 703 Quick Reference: Age Requirements: Typically 18+ for adults Some medications approved for age 12+ (with parental consent) Contraindications (Cannot Prescribe If Present): Absolute Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnancy or planning pregnancy within 2 months Breastfeeding Previous severe allergic reaction to GLP-1 medications Relative Contraindications (May Preclude or Require Caution): History of pancreatitis Severe gastroparesis Active eating disorder (anorexia, bulimia) Severe kidney disease Active gallbladder disease Diabetic retinopathy (recent diagnosis) Medication Considerations May Require Dose Adjustments: Currently taking insulin On sulfonylureas (diabetes medications) Taking blood thinners (warfarin) Generally Compatible: Blood pressure medications Cholesterol medications Most antidepressants Thyroid medications Provider will review all current medications during consultation

This is data

How to activate GLP-1 naturally GLP-1, which stands for glucagon-like peptide, is a hormone that your small intestine makes after you eat

Beyond weight loss, SELECT demonstrated a 20% reduction in major cardiovascular eventsheart attacks, strokes, and cardiovascular deathin people with obesity and established heart disease

It is not suitable for individuals with: A personal or family history of medullary thyroid carcinoma (MTC) Multiple endocrine neoplasia syndrome type 2 (MEN 2) Severe kidney disease without medical consultation Always consult your healthcare provider to determine if GLP-1 is right for you